|
|
|
22.06.26 - 23:18
|
Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal (ZeroHedge)
|
|
|
Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal
Definium Therapeutics shares surged as much as 54% on Monday, reaching $37.90 in morning trading as investors reacted positively to developments in the biotech company's research pipeline and potential strategic opportunities.
Definium Therapeutics said its LSD-based depression drug, DT120, met the main goal of a mid-stage trial, reducing depression scores by 8.1 points more than placebo after six weeks, according to Reuters.
Patients showed improvement within one week after a single dose, with benefits remaining at 12 weeks. Analysts had said a 4–5 point placebo-adjusted improvement would be a strong result.
DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on dosing day and no serious safety concerns.
The trial included 149 adults with major depressive disorder, a condition affecting about 21 million U.S. adults. Re...
|
|
|
|
|
|
|
22.06.26 - 22:06
|
Definium Therapeutics, Inc. Announces Proposed Public Offering (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, Definium intends to grant the underwriters an option for a period of 30 days to purchase up to $75 million of its common shares at the public offering price, less underwriting discounts and commissions. All of the common shares and pre-funded warrants are being offered by Definium.
Definium intends to use the net proceeds from this offering for the research and development of its product candidates, preparation activities for potential commercialization of DT120 ODT, if approved, and working capi...
|
|
|
|
|
|
|
|
|
15.06.26 - 22:06
|
Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 155,480 common shares of the Company (the "Options") with effective grant dates of June 15, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employment and were approved by Definium's Comp...
|
|
|
|
|
11.05.26 - 22:03
|
Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 255,340 common shares of the Company (the "Options") with effective grant dates of April 27, 2026, May 4, 2026 and May 11, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employ...
|
|
|
|
|
|
|
07.05.26 - 22:03
|
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (Business Wire)
|
|
|
Three Phase 3 topline data readouts for DT120 ODT expected in the coming months
DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027
$373.4 million in cash, cash equivalents, and investments as of March 31, 2026, expected to fund operations into 2028
Conference call scheduled today at 4:30 p.m. EDTNEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended March 31, 2026, and recent highlights.
“After an exceptionally productive start to 2026, we are thrilled to enter an exciting and transformative period for Definium, marked by three pivotal data readouts for DT120 ODT anticipated within the next five months and an expanded development program in PTSD,” said Rob Barrow, Chief Executive Offi...
|
|
|
30.04.26 - 22:03
|
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, May 7, 2026 to report financial results for the first quarter ended March 31, 2026, and discuss recent business highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About Definium Therapeutics
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the...
|
|
|
|
|
20.04.26 - 23:54
|
Compass Pathways CEO on Trump′s Order to Expand Psychedelics Research (Bloomberg)
|
|
|
Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shortening the review time to one to two months from six to ten months. AtaiBeckley, Definium and Compass Pathways all have therapies with breakthrough status. Compass Pathways CEO Kabir Nath joins Bloomberg Businessweek Daily to discuss. He speaks with Carol Massar and Tim Stenovec. (Source: Bloomberg)...
|
|
|
20.04.26 - 22:03
|
Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 70,860 common shares of the Company (the "Options") with effective grant dates of April 6, 2026 and April 20, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employment and were...
|
|
|
30.03.26 - 22:06
|
Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 55,580 common shares of the Company (the "Options") with effective grant dates of March 16, 2026 and March 30, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employment and we...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
